Therapeutic treatment of marburg and ravn virus infection in nonhuman primates with a human monoclonal antibody

Chad Mire, Joan B. Geisbert, Viktoriya Borisevich, Karla A. Fenton, Krystle N. Agans, Andrew I. Flyak, Daniel J. Deer, Herta Steinkellner, Ognian Bohorov, Natasha Bohorova, Charles Goodman, Andrew Hiatt, Do H. Kim, Michael H. Pauly, Jesus Velasco, Kevin J. Whaley, James E. Crowe, Larry Zeitlin, Thomas Geisbert

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

As observed during the 2013-2016 Ebola virus disease epidemic, containment of filovirus outbreaks is challenging and made more difficult by the lack of approved vaccine or therapeutic options. Marburg and Ravn viruses are highly virulent and cause severe and frequently lethal disease in humans. Monoclonal antibodies (mAbs) are a platform technology in wide use for autoimmune and oncology indications. Previously, we described human mAbs that can protect mice from lethal challenge with Marburg virus. We demonstrate that one of these mAbs, MR191-N, can confer a survival benefit of up to 100% to Marburg or Ravn virus-infected rhesus macaques when treatment is initiated up to 5 days post-inoculation. These findings extend the small but growing body of evidence that mAbs can impart therapeutic benefit during advanced stages of disease with highly virulent viruses and could be useful in epidemic settings.

Original languageEnglish (US)
Article numbereaai8711
JournalScience Translational Medicine
Volume9
Issue number384
DOIs
StatePublished - Apr 5 2017

Fingerprint

Marburgvirus
Virus Diseases
Primates
Monoclonal Antibodies
Ebola Hemorrhagic Fever
Viruses
Therapeutics
Macaca mulatta
Disease Outbreaks
Vaccines
Technology
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Therapeutic treatment of marburg and ravn virus infection in nonhuman primates with a human monoclonal antibody. / Mire, Chad; Geisbert, Joan B.; Borisevich, Viktoriya; Fenton, Karla A.; Agans, Krystle N.; Flyak, Andrew I.; Deer, Daniel J.; Steinkellner, Herta; Bohorov, Ognian; Bohorova, Natasha; Goodman, Charles; Hiatt, Andrew; Kim, Do H.; Pauly, Michael H.; Velasco, Jesus; Whaley, Kevin J.; Crowe, James E.; Zeitlin, Larry; Geisbert, Thomas.

In: Science Translational Medicine, Vol. 9, No. 384, eaai8711, 05.04.2017.

Research output: Contribution to journalArticle

Mire, C, Geisbert, JB, Borisevich, V, Fenton, KA, Agans, KN, Flyak, AI, Deer, DJ, Steinkellner, H, Bohorov, O, Bohorova, N, Goodman, C, Hiatt, A, Kim, DH, Pauly, MH, Velasco, J, Whaley, KJ, Crowe, JE, Zeitlin, L & Geisbert, T 2017, 'Therapeutic treatment of marburg and ravn virus infection in nonhuman primates with a human monoclonal antibody', Science Translational Medicine, vol. 9, no. 384, eaai8711. https://doi.org/10.1126/scitranslmed.aai8711
Mire, Chad ; Geisbert, Joan B. ; Borisevich, Viktoriya ; Fenton, Karla A. ; Agans, Krystle N. ; Flyak, Andrew I. ; Deer, Daniel J. ; Steinkellner, Herta ; Bohorov, Ognian ; Bohorova, Natasha ; Goodman, Charles ; Hiatt, Andrew ; Kim, Do H. ; Pauly, Michael H. ; Velasco, Jesus ; Whaley, Kevin J. ; Crowe, James E. ; Zeitlin, Larry ; Geisbert, Thomas. / Therapeutic treatment of marburg and ravn virus infection in nonhuman primates with a human monoclonal antibody. In: Science Translational Medicine. 2017 ; Vol. 9, No. 384.
@article{388d24dd43174b2ebd9c1511dee52414,
title = "Therapeutic treatment of marburg and ravn virus infection in nonhuman primates with a human monoclonal antibody",
abstract = "As observed during the 2013-2016 Ebola virus disease epidemic, containment of filovirus outbreaks is challenging and made more difficult by the lack of approved vaccine or therapeutic options. Marburg and Ravn viruses are highly virulent and cause severe and frequently lethal disease in humans. Monoclonal antibodies (mAbs) are a platform technology in wide use for autoimmune and oncology indications. Previously, we described human mAbs that can protect mice from lethal challenge with Marburg virus. We demonstrate that one of these mAbs, MR191-N, can confer a survival benefit of up to 100{\%} to Marburg or Ravn virus-infected rhesus macaques when treatment is initiated up to 5 days post-inoculation. These findings extend the small but growing body of evidence that mAbs can impart therapeutic benefit during advanced stages of disease with highly virulent viruses and could be useful in epidemic settings.",
author = "Chad Mire and Geisbert, {Joan B.} and Viktoriya Borisevich and Fenton, {Karla A.} and Agans, {Krystle N.} and Flyak, {Andrew I.} and Deer, {Daniel J.} and Herta Steinkellner and Ognian Bohorov and Natasha Bohorova and Charles Goodman and Andrew Hiatt and Kim, {Do H.} and Pauly, {Michael H.} and Jesus Velasco and Whaley, {Kevin J.} and Crowe, {James E.} and Larry Zeitlin and Thomas Geisbert",
year = "2017",
month = "4",
day = "5",
doi = "10.1126/scitranslmed.aai8711",
language = "English (US)",
volume = "9",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "384",

}

TY - JOUR

T1 - Therapeutic treatment of marburg and ravn virus infection in nonhuman primates with a human monoclonal antibody

AU - Mire, Chad

AU - Geisbert, Joan B.

AU - Borisevich, Viktoriya

AU - Fenton, Karla A.

AU - Agans, Krystle N.

AU - Flyak, Andrew I.

AU - Deer, Daniel J.

AU - Steinkellner, Herta

AU - Bohorov, Ognian

AU - Bohorova, Natasha

AU - Goodman, Charles

AU - Hiatt, Andrew

AU - Kim, Do H.

AU - Pauly, Michael H.

AU - Velasco, Jesus

AU - Whaley, Kevin J.

AU - Crowe, James E.

AU - Zeitlin, Larry

AU - Geisbert, Thomas

PY - 2017/4/5

Y1 - 2017/4/5

N2 - As observed during the 2013-2016 Ebola virus disease epidemic, containment of filovirus outbreaks is challenging and made more difficult by the lack of approved vaccine or therapeutic options. Marburg and Ravn viruses are highly virulent and cause severe and frequently lethal disease in humans. Monoclonal antibodies (mAbs) are a platform technology in wide use for autoimmune and oncology indications. Previously, we described human mAbs that can protect mice from lethal challenge with Marburg virus. We demonstrate that one of these mAbs, MR191-N, can confer a survival benefit of up to 100% to Marburg or Ravn virus-infected rhesus macaques when treatment is initiated up to 5 days post-inoculation. These findings extend the small but growing body of evidence that mAbs can impart therapeutic benefit during advanced stages of disease with highly virulent viruses and could be useful in epidemic settings.

AB - As observed during the 2013-2016 Ebola virus disease epidemic, containment of filovirus outbreaks is challenging and made more difficult by the lack of approved vaccine or therapeutic options. Marburg and Ravn viruses are highly virulent and cause severe and frequently lethal disease in humans. Monoclonal antibodies (mAbs) are a platform technology in wide use for autoimmune and oncology indications. Previously, we described human mAbs that can protect mice from lethal challenge with Marburg virus. We demonstrate that one of these mAbs, MR191-N, can confer a survival benefit of up to 100% to Marburg or Ravn virus-infected rhesus macaques when treatment is initiated up to 5 days post-inoculation. These findings extend the small but growing body of evidence that mAbs can impart therapeutic benefit during advanced stages of disease with highly virulent viruses and could be useful in epidemic settings.

UR - http://www.scopus.com/inward/record.url?scp=85017420711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017420711&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aai8711

DO - 10.1126/scitranslmed.aai8711

M3 - Article

VL - 9

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 384

M1 - eaai8711

ER -